Business
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
ProtoKinetix AAGP® Dry Eye Therapy Testing Results.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\nProtoKinetix, Incorporated (www.protokinetix.com) (the \"Company\" or \"ProtoKinetix\") (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation.\n\n\nAbout ITR Laboratories\n\n\nBased on this ProtoKinetix is shipping AAGP® to EyeCRO to commence testing Dry Eye Disease efficacy. This testing will involve topical application of AAGP® and evaluations of its effects on ocular inflammation. EyeCRO is a world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.\n\n\nAbout EyeCRO\n\n\nAbout Dry Eye Disease\n\n\nDry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.\n\n\nAbout ProtoKinetix, Incorporated\n\n\nProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.\n\n\nFor more Company information and to join our email listing visit our website at ProtoKinetix.com.\n\n\nCautionary Note Regarding Forward-Looking Statements \n\n\nThe information discussed in this press release includes “forward looking statement...